entertainment -WSS

entertainment

author：focus 2025-09-01 05:55:27 - browse：18

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： A timeline of the missing Titanic tourist submersible

explore

WSS

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

NASA releases new images of 'fingerprint

Some in Scotland's Orkney Islands want to return to Norway after 550 years

Hey, doctors: Don't be no

New chart reveals military’s vast involvement in Operation Warp Speed

New chart reveals military’s vast involvement in Operation Warp Speed

focus

entertainment

focus

Hepatitis C has a cure — but many Americans still lack access to it

Elon Musk announces 'temporary limits' for reading Twitter posts

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Some in Scotland's Orkney Islands want to return to Norway after 550 years

At least 13 dead in Texas as scorching temps continue

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

23andMe had bad news about my health. I wish a person had delivered it

How Brent Saunders' Allergan experiment failed

Drug repurposing or repositioning? The language matters

NASA releases new images of 'fingerprint

focus

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

US judge blocks portions of new Florida elections law

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

Pfizer's RSV vaccine recommended for approval in Europe

Elon Musk announces 'temporary limits' for reading Twitter posts

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

knowledge

explore

focus

focus